Enterome presented its findings to the 17th International Conference on Malignant Lymphoma (ICML) in June of this year. As reported in the GlobeNewswire, the company demonstrated that E02463 together with the standard of care produces favorable immune responses.
About Non-Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma is a cancer of the white blood cells of the immune or lymphatic system. It is characteristically slow growing and usually does not have symptoms. Hodgkin’s lymphoma and non-Hodgkin’s lymphoma differ according to the cell type they attack.
OncoMimics™ E02463, an experimental vaccine is an innovative therapeutic treatment that has shown efficacy and reassuring safety in a Phase 1/2 trial for indolent non-Hodgkin lymphoma (iNHL).
The vaccine uses four OncoMimics™ (bacterial peptides) to induce the depletion of any malignant B lymphocytes carrying high levels of iNHL. Peptides are short chains of amino acids that are part of the immune system.
The Evaluation of E02463
E02463 is a peptide therapeutic vaccine administered either in combination with rituximab and/or lenalidomide or as a monotherapy in eligible patients diagnosed with indolent NHL. The study (NCT04669171) is designed to establish safety and efficacy data in eligible patients.
Positive responses followed a six-week period of E02463 treatment combined with rituximab and lenalidomide. 50% of the eligible patients participated.
EO2463 targets multiple B cell markers and is instrumental in destroying malignant B lymphocytes found in abundance in iNHL.
According to Jan Fagerberg M.D. Enterome’s CMO, E02436 was created with the intention of expanding previously existing memory cytotoxic T cells and identifying protein sequences found in gut bacteria.
The gut bacteria cross-react with the B cell proteins and directs anti-tumor action in B cell cancers.
E02463 shows promising efficacy in NHL, thus confirming OncoMimic-immunotherapy’s potential against liquid tumors.